Pfizer(US:PFE) Zhi Tong Cai Jing·2025-12-16 15:42Core Viewpoint - Pfizer (PFE.US) shares fell over 4% to $25.27 as the company forecasts minimal or no sales growth for the upcoming year due to efforts to revamp its drug portfolio through expensive acquisitions [1] Group 1: Financial Projections - Pfizer expects revenue for 2026 to be between $59.5 billion and $62.5 billion, aligning with Wall Street expectations [1] - The company anticipates 2023 sales to be approximately $62 billion, consistent with its guidance from early November [1] - Adjusted earnings per share for the next year are projected to be between $2.80 and $3.00 [1] Group 2: Market Challenges - CEO Albert Bourla is facing a critical moment in revitalizing Pfizer as the demand for COVID-19 vaccines and treatments, which previously drove sales growth, is declining [1] - Revenue from COVID-related products is expected to decrease by approximately $1.5 billion to $5 billion next year [1]